Giao dịch iBio, Inc. - IBIO CFD

Điều kiện giao dịch

• Loại: CFD
• Chênh lệch: 0.0260
• Điều chỉnh phí tài trợ qua đêm cho vị thế mua: -0.02157%
• Điều chỉnh phí tài trợ qua đêm cho vị thế bán: -0.00065%
• Thời gian điều chỉnh phí tài trợ qua đêm: 22:00 (UTC)
• Tiền tệ: USD
• Số lượng giao dịch tối thiểu: 10
• Biên lợi nhuận: 5.00%
• Sàn giao dịch chứng khoán: United States of America
• Phí hoa hồng giao dịch: 0%
• Bảo đảm dừng phí bảo hiểm: 1%

Số liệu thống kê chính

• Trước đó Đóng: 2.147
• Mở: 2.137
• Thay đổi 1 năm: -26.74%
• Phạm vi trong ngày: 2.067 - 2.137

iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company''s services cover the stages of pre-clinical development, regulatory approval, commercial product launch, and on-going commercial phase requirements. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. The company is also developing vaccine candidates for third parties. It has a license agreement with the University of Natural Resources and Life Sciences, Vienna; a strategic relationship with Beijing CC-Pharming Ltd.; and collaboration agreements with AzarGen Biotechnologies (Pty) Ltd, The Texas A&M University System, and Fraunhofer Center for Molecular Biotechnology. In addition, the company offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.